3 completed. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
Follow BIO89-100: new trials by email Literature Review of BIO89-100 trials Research Report on BIO89-100
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH) BIO89-100, Placebo - NASH - Nonalcoholic Steatohepatitis | Phase 2 | Completed | 89bio, Inc. | 222 | 2021-06-04 | 2026-01-06 |
| Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia Pegozafermin, Placebo - Severe Hypertriglyceridemia | Phase 2 | Completed | 89bio, Inc. | 86 | 2020-09-01 | 2024-07-25 |
| A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH Pegozafermin, Placebo - NASH | Phase 1 / Phase 2 | Completed | 89bio, Inc. | 101 | 2019-07-29 | 2024-04-02 |
Fatty Liver (2) · Liver Diseases (2) · Metabolic Diseases (2) · Non-alcoholic Fatty Liver Disease (2) · Digestive System Diseases (1) · Dyslipidemias (1) · Hypertriglyceridemia (1) · Lipid Metabolism Disorders (1)
89bio, Inc. (3)
United States (3) · Puerto Rico (2) · Czechia (1) · Hungary (1) · Poland (1)
PMID 37696614, PMID 36521501, PMID 37355760, PMID 37356033, PMID 37718721